Skip to main content

Recent News

  • meeting.audience.3_0.jpg

    Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:

    Read Article

Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA

Eric Dein, MD

Which of our RA patients will develop interstitial lung disease (RA-ILD), and how can we better identify these patients? In abstract #2884 at 2026 ACR Convergence, Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study evaluating risk factors for ILD in at-risk patients with RA without a known diagnosis. The goal was to identify the clinical characteristics that can guide screening for RA-ILD.

Mrinalini Dey
@DrMiniDey
How much RA-ILD are we missing? HRCT detected previously undiagnosed ILD in 9.1% of 1169 RA patients with >=2 risk factors. FVC was similar with and without ILD; crackles and lower DLCO were more common with ILD. #2884 #ACR26 @Rheumnow
Janet Pope
@Janetbirdope
If #rituximab doesn’t improve #mrRSS #skin #score at 1 yr; unlikely to improve in Yr 2 in #SSc Didn’t matter if sustained B cell depletion and Rx effect Strange as I think mRSS can still work in Y2 Rx in #scleroderma #dcSSc but with some effect in yr1 #2906 #ACR26 @RheumNow https://t.co/5pEy45W6uh
Janet Pope
@Janetbirdope
Composite endpoint to see if #scleroderma #SSc can be treated by #nerandomilast Beyond #PPF Complicated as so many organs and many different progression rates for various organs A #basket #trial of #outcomes? Novel outcomes will be used Abst#2905 @ACRheum @RheumNow #ACR26 https://t.co/lQwqqRh1q4
Mrinalini Dey
@DrMiniDey
FLEET-RA: HRCT found subclinical/undiagnosed ILD in 13.6% of 390 RA patients. MUC5B risk variant was associated with higher odds (OR 3.58), alongside age, sex, smoking, RF and activity. Potential for targeted screening. @Rheumnow #2883 #ACR26
×